StockData
Immuneering Corp logo

Immuneering Corp (IMRX) stock

IMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 8/30
$3.50+0.04 (+1.16%)

Close on Nov 18, 2026Market cap $226.67MP/E –Yield –

Immuneering gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

Immuneering's gross profit for the twelve months ending Dec 31, 2023 was $0, down 100.0% year over year. For fiscal 2023 it was $0, down 100.0% from the year before.

Annual gross profit

PeriodPeriod endValueChange
FY2023Dec 31, 2023$0-100.0%
FY2022Dec 31, 2022$158.83K-82.9%
FY2021Dec 31, 2021$926.89K-10.1%
FY2020Dec 31, 2020$1.03M–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2023Dec 31, 2023$0-100.0%
Q3 FY2023Sep 30, 2023$0-100.0%
Q2 FY2023Jun 30, 2023$0-100.0%
Q1 FY2023Mar 31, 2023$0-100.0%
Q4 FY2022Dec 31, 2022$455–
Q3 FY2022Sep 30, 2022$19.04K-92.8%
Q2 FY2022Jun 30, 2022$46.49K-86.4%
Q1 FY2022Mar 31, 2022$92.85K-72.6%
Q4 FY2021Dec 31, 2021-$16.63K-108.7%
Q3 FY2021Sep 30, 2021$263.04K-28.4%
Q2 FY2021Jun 30, 2021$341.44K+40.1%
Q1 FY2021Mar 31, 2021$339.04K–
Q4 FY2020Dec 31, 2020$191.85K–
Q3 FY2020Sep 30, 2020$367.57K–
Q2 FY2020Jun 30, 2020$243.77K–

More Immuneering figures

See a number that looks wrong?